SACUBITRIL-VALSARTAN FOLLOWING HOSPITAL DISCHARGE FOR HEART FAILURE

Lauren B. Cooper,Lisa A. Kaltenbach,Hussein R. Al-Khalidi,Robert T. Cole,Larry A. Allen,Gregg C. Fonarow,Javed Butler,Nancy M. Albert,David E. Lanfear,Bradi B. Granger,Robb D. Kociol,Ileana L. Piña,Paul A. Heidenreich,Christopher B. Granger,G. Michael Felker,Eldrin F. Lewis,Andrew T. McRae,Adrian F. Hernandez,Adam D. DeVore

SACUBITRIL-VALSARTAN FOLLOWING HOSPITAL DISCHARGE FOR HEART FAILURE

2020

Lauren B. Cooper
Lisa A. Kaltenbach
Hussein R. Al-Khalidi
Robert T. Cole
Larry A. Allen
Gregg C. Fonarow
Javed Butler
Nancy M. Albert
David E. Lanfear
Bradi B. Granger
Robb D. Kociol
Ileana L. Piña
Paul A. Heidenreich
Christopher B. Granger
G. Michael Felker
Eldrin F. Lewis
Andrew T. McRae
Adrian F. Hernandez
Adam D. DeVore

Angiotensin receptor-neprilysin inhibitors (ARNIs) reduce mortality and heart failure (HF) hospitalization in acute and chronic HF with reduced ejection fraction. The uptake and utilization of this medication in routine clinical practice is evolving. Among 3875 patients enrolled in the CONNECT-HF

Keywords:

Diabetes mellitus
Sacubitril, Valsartan
Cardiology
Medicine
Internal medicine
Heart failure
Renin–angiotensin system
Ejection fraction
routine clinical practice
hospital discharge

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations